nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—MAP3K3—esophageal cancer	0.371	0.596	CbGaD
Dasatinib—ABL1—esophageal cancer	0.137	0.221	CbGaD
Dasatinib—CYP1B1—esophageal cancer	0.0884	0.142	CbGaD
Dasatinib—ABCB1—esophageal cancer	0.0254	0.0408	CbGaD
Dasatinib—ABCG2—Carboplatin—esophageal cancer	0.00675	0.343	CbGbCtD
Dasatinib—ABCG2—Cisplatin—esophageal cancer	0.00577	0.293	CbGbCtD
Dasatinib—ABCG2—Methotrexate—esophageal cancer	0.00375	0.19	CbGbCtD
Dasatinib—ABCB1—Cisplatin—esophageal cancer	0.00208	0.106	CbGbCtD
Dasatinib—PKMYT1—neck—esophageal cancer	0.00166	0.0178	CbGeAlD
Dasatinib—ABCB1—Methotrexate—esophageal cancer	0.00135	0.0686	CbGbCtD
Dasatinib—ERBB3—exocrine gland—esophageal cancer	0.00135	0.0145	CbGeAlD
Dasatinib—BMX—epithelium—esophageal cancer	0.0011	0.0118	CbGeAlD
Dasatinib—SRMS—bronchus—esophageal cancer	0.00104	0.0111	CbGeAlD
Dasatinib—PTK6—bronchus—esophageal cancer	0.00102	0.0109	CbGeAlD
Dasatinib—STAT5B—epithelium—esophageal cancer	0.000976	0.0105	CbGeAlD
Dasatinib—PTK6—trachea—esophageal cancer	0.000913	0.00978	CbGeAlD
Dasatinib—KIT—exocrine gland—esophageal cancer	0.000826	0.00885	CbGeAlD
Dasatinib—EPHB2—digestive system—esophageal cancer	0.000819	0.00878	CbGeAlD
Dasatinib—ZAK—bronchus—esophageal cancer	0.000803	0.00861	CbGeAlD
Dasatinib—MAPK14—neck—esophageal cancer	0.000803	0.00861	CbGeAlD
Dasatinib—SRMS—digestive system—esophageal cancer	0.000801	0.00859	CbGeAlD
Dasatinib—PTK6—digestive system—esophageal cancer	0.000785	0.00842	CbGeAlD
Dasatinib—BMPR1B—epithelium—esophageal cancer	0.000782	0.00838	CbGeAlD
Dasatinib—BMPR1B—bronchus—esophageal cancer	0.00077	0.00826	CbGeAlD
Dasatinib—BTK—bronchus—esophageal cancer	0.000766	0.00822	CbGeAlD
Dasatinib—STAT5B—digestive system—esophageal cancer	0.000742	0.00796	CbGeAlD
Dasatinib—TEC—lymph node—esophageal cancer	0.000726	0.00778	CbGeAlD
Dasatinib—TESK1—bronchus—esophageal cancer	0.00071	0.00761	CbGeAlD
Dasatinib—BMX—lung—esophageal cancer	0.0007	0.0075	CbGeAlD
Dasatinib—STK36—bronchus—esophageal cancer	0.000699	0.00749	CbGeAlD
Dasatinib—EPHB3—bronchus—esophageal cancer	0.000699	0.00749	CbGeAlD
Dasatinib—LIMK2—bronchus—esophageal cancer	0.000676	0.00724	CbGeAlD
Dasatinib—SRMS—lung—esophageal cancer	0.000669	0.00717	CbGeAlD
Dasatinib—TXK—lung—esophageal cancer	0.000662	0.0071	CbGeAlD
Dasatinib—PTK6—lung—esophageal cancer	0.000656	0.00703	CbGeAlD
Dasatinib—CSK—bronchus—esophageal cancer	0.000651	0.00697	CbGeAlD
Dasatinib—HCK—bronchus—esophageal cancer	0.000642	0.00688	CbGeAlD
Dasatinib—TESK1—trachea—esophageal cancer	0.000638	0.00684	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—esophageal cancer	0.000637	0.00682	CbGeAlD
Dasatinib—EPHB3—trachea—esophageal cancer	0.000628	0.00673	CbGeAlD
Dasatinib—STK36—trachea—esophageal cancer	0.000628	0.00673	CbGeAlD
Dasatinib—ZAK—digestive system—esophageal cancer	0.000621	0.00665	CbGeAlD
Dasatinib—STAT5B—lung—esophageal cancer	0.00062	0.00665	CbGeAlD
Dasatinib—RIPK2—epithelium—esophageal cancer	0.000613	0.00657	CbGeAlD
Dasatinib—EPHA5—digestive system—esophageal cancer	0.000607	0.00651	CbGeAlD
Dasatinib—LIMK2—trachea—esophageal cancer	0.000607	0.0065	CbGeAlD
Dasatinib—RIPK2—bronchus—esophageal cancer	0.000604	0.00647	CbGeAlD
Dasatinib—SIK1—bronchus—esophageal cancer	0.00059	0.00632	CbGeAlD
Dasatinib—ERBB3—epithelium—esophageal cancer	0.000587	0.00629	CbGeAlD
Dasatinib—CSK—trachea—esophageal cancer	0.000584	0.00626	CbGeAlD
Dasatinib—EPHA4—bronchus—esophageal cancer	0.000584	0.00626	CbGeAlD
Dasatinib—HCK—trachea—esophageal cancer	0.000577	0.00618	CbGeAlD
Dasatinib—EPHA3—lung—esophageal cancer	0.000573	0.00614	CbGeAlD
Dasatinib—EPHB1—lymph node—esophageal cancer	0.00057	0.00611	CbGeAlD
Dasatinib—SIK3—lung—esophageal cancer	0.000558	0.00598	CbGeAlD
Dasatinib—MAPK14—epithelium—esophageal cancer	0.000547	0.00586	CbGeAlD
Dasatinib—RIPK2—trachea—esophageal cancer	0.000542	0.00581	CbGeAlD
Dasatinib—EPHB3—digestive system—esophageal cancer	0.00054	0.00579	CbGeAlD
Dasatinib—MAPK14—bronchus—esophageal cancer	0.000538	0.00577	CbGeAlD
Dasatinib—LCK—bronchus—esophageal cancer	0.000536	0.00575	CbGeAlD
Dasatinib—KIT—neck—esophageal cancer	0.000528	0.00566	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—esophageal cancer	0.000527	0.00564	CbGeAlD
Dasatinib—EPHA4—trachea—esophageal cancer	0.000524	0.00562	CbGeAlD
Dasatinib—ERBB3—trachea—esophageal cancer	0.000519	0.00556	CbGeAlD
Dasatinib—ZAK—lung—esophageal cancer	0.000518	0.00556	CbGeAlD
Dasatinib—EPHB4—epithelium—esophageal cancer	0.000518	0.00555	CbGeAlD
Dasatinib—FMO3—bronchus—esophageal cancer	0.000518	0.00555	CbGeAlD
Dasatinib—PDGFRB—neck—esophageal cancer	0.000516	0.00553	CbGeAlD
Dasatinib—JAK2—epithelium—esophageal cancer	0.000514	0.00551	CbGeAlD
Dasatinib—EPHB4—bronchus—esophageal cancer	0.00051	0.00547	CbGeAlD
Dasatinib—EPHA2—epithelium—esophageal cancer	0.000508	0.00545	CbGeAlD
Dasatinib—JAK2—bronchus—esophageal cancer	0.000507	0.00543	CbGeAlD
Dasatinib—CSK—digestive system—esophageal cancer	0.000503	0.00539	CbGeAlD
Dasatinib—EPHA2—bronchus—esophageal cancer	0.000501	0.00537	CbGeAlD
Dasatinib—FYN—bronchus—esophageal cancer	0.0005	0.00536	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—esophageal cancer	0.000499	0.00535	CbGeAlD
Dasatinib—MAP3K19—lung—esophageal cancer	0.000497	0.00533	CbGeAlD
Dasatinib—BMPR1B—lung—esophageal cancer	0.000497	0.00533	CbGeAlD
Dasatinib—HCK—digestive system—esophageal cancer	0.000496	0.00532	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—esophageal cancer	0.000496	0.00531	CbGeAlD
Dasatinib—BTK—lung—esophageal cancer	0.000495	0.0053	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—esophageal cancer	0.000489	0.00524	CbGeAlD
Dasatinib—MAP4K5—bronchus—esophageal cancer	0.000488	0.00523	CbGeAlD
Dasatinib—MAP3K3—bronchus—esophageal cancer	0.000488	0.00523	CbGeAlD
Dasatinib—TNK2—lung—esophageal cancer	0.000487	0.00522	CbGeAlD
Dasatinib—LCK—trachea—esophageal cancer	0.000481	0.00516	CbGeAlD
Dasatinib—BMX—lymph node—esophageal cancer	0.000479	0.00513	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—esophageal cancer	0.000478	0.00512	CbGeAlD
Dasatinib—BLK—lymph node—esophageal cancer	0.000473	0.00507	CbGeAlD
Dasatinib—EPHB6—bronchus—esophageal cancer	0.000467	0.005	CbGeAlD
Dasatinib—RIPK2—digestive system—esophageal cancer	0.000467	0.005	CbGeAlD
Dasatinib—TESK1—lung—esophageal cancer	0.000458	0.00491	CbGeAlD
Dasatinib—EPHB4—trachea—esophageal cancer	0.000458	0.00491	CbGeAlD
Dasatinib—JAK2—trachea—esophageal cancer	0.000455	0.00488	CbGeAlD
Dasatinib—TXK—lymph node—esophageal cancer	0.000453	0.00486	CbGeAlD
Dasatinib—YES1—bronchus—esophageal cancer	0.000451	0.00483	CbGeAlD
Dasatinib—STK36—lung—esophageal cancer	0.000451	0.00483	CbGeAlD
Dasatinib—EPHB3—lung—esophageal cancer	0.000451	0.00483	CbGeAlD
Dasatinib—EPHA2—trachea—esophageal cancer	0.000449	0.00482	CbGeAlD
Dasatinib—FYN—trachea—esophageal cancer	0.000449	0.00481	CbGeAlD
Dasatinib—ERBB3—digestive system—esophageal cancer	0.000447	0.00479	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—esophageal cancer	0.000441	0.00473	CbGeAlD
Dasatinib—SRC—epithelium—esophageal cancer	0.000441	0.00472	CbGeAlD
Dasatinib—MAP3K3—trachea—esophageal cancer	0.000438	0.0047	CbGeAlD
Dasatinib—MAP4K5—trachea—esophageal cancer	0.000438	0.0047	CbGeAlD
Dasatinib—LIMK2—lung—esophageal cancer	0.000436	0.00467	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000433	0.00464	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—esophageal cancer	0.000425	0.00455	CbGeAlD
Dasatinib—STAT5B—lymph node—esophageal cancer	0.000424	0.00455	CbGeAlD
Dasatinib—STK35—lung—esophageal cancer	0.000423	0.00453	CbGeAlD
Dasatinib—CSK—lung—esophageal cancer	0.00042	0.0045	CbGeAlD
Dasatinib—EPHB6—trachea—esophageal cancer	0.000419	0.00449	CbGeAlD
Dasatinib—MAPK14—digestive system—esophageal cancer	0.000416	0.00446	CbGeAlD
Dasatinib—HCK—lung—esophageal cancer	0.000414	0.00444	CbGeAlD
Dasatinib—FGR—digestive system—esophageal cancer	0.000414	0.00444	CbGeAlD
Dasatinib—ABL2—lung—esophageal cancer	0.000412	0.00441	CbGeAlD
Dasatinib—YES1—trachea—esophageal cancer	0.000405	0.00434	CbGeAlD
Dasatinib—MAP2K5—bronchus—esophageal cancer	0.000399	0.00428	CbGeAlD
Dasatinib—PDGFRA—trachea—esophageal cancer	0.000397	0.00426	CbGeAlD
Dasatinib—EPHB4—digestive system—esophageal cancer	0.000394	0.00423	CbGeAlD
Dasatinib—EPHA3—lymph node—esophageal cancer	0.000392	0.0042	CbGeAlD
Dasatinib—JAK2—digestive system—esophageal cancer	0.000391	0.0042	CbGeAlD
Dasatinib—RIPK2—lung—esophageal cancer	0.00039	0.00418	CbGeAlD
Dasatinib—CSF1R—bronchus—esophageal cancer	0.00039	0.00417	CbGeAlD
Dasatinib—EPHA2—digestive system—esophageal cancer	0.000387	0.00414	CbGeAlD
Dasatinib—FYN—digestive system—esophageal cancer	0.000386	0.00414	CbGeAlD
Dasatinib—SIK3—lymph node—esophageal cancer	0.000381	0.00409	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—esophageal cancer	0.000381	0.00408	CbGeAlD
Dasatinib—SIK1—lung—esophageal cancer	0.00038	0.00408	CbGeAlD
Dasatinib—EPHA4—lung—esophageal cancer	0.000377	0.00404	CbGeAlD
Dasatinib—ERBB3—lung—esophageal cancer	0.000373	0.004	CbGeAlD
Dasatinib—MAP3K2—lung—esophageal cancer	0.000369	0.00396	CbGeAlD
Dasatinib—KIT—epithelium—esophageal cancer	0.000359	0.00385	CbGeAlD
Dasatinib—MAP2K5—trachea—esophageal cancer	0.000358	0.00384	CbGeAlD
Dasatinib—ZAK—lymph node—esophageal cancer	0.000355	0.0038	CbGeAlD
Dasatinib—KIT—bronchus—esophageal cancer	0.000354	0.00379	CbGeAlD
Dasatinib—PDGFRB—epithelium—esophageal cancer	0.000351	0.00376	CbGeAlD
Dasatinib—CSF1R—trachea—esophageal cancer	0.00035	0.00375	CbGeAlD
Dasatinib—YES1—digestive system—esophageal cancer	0.000348	0.00373	CbGeAlD
Dasatinib—MAPK14—lung—esophageal cancer	0.000347	0.00372	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—esophageal cancer	0.000346	0.00371	CbGeAlD
Dasatinib—FGR—lung—esophageal cancer	0.000346	0.00371	CbGeAlD
Dasatinib—LCK—lung—esophageal cancer	0.000346	0.00371	CbGeAlD
Dasatinib—PDGFRB—bronchus—esophageal cancer	0.000345	0.0037	CbGeAlD
Dasatinib—PDGFRA—digestive system—esophageal cancer	0.000342	0.00366	CbGeAlD
Dasatinib—BMPR1B—lymph node—esophageal cancer	0.00034	0.00364	CbGeAlD
Dasatinib—BTK—lymph node—esophageal cancer	0.000338	0.00363	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000338	0.00362	CbGeAlD
Dasatinib—SRC—digestive system—esophageal cancer	0.000335	0.00359	CbGeAlD
Dasatinib—FMO3—lung—esophageal cancer	0.000334	0.00358	CbGeAlD
Dasatinib—TNK2—lymph node—esophageal cancer	0.000333	0.00357	CbGeAlD
Dasatinib—EPHB4—lung—esophageal cancer	0.000329	0.00353	CbGeAlD
Dasatinib—JAK2—lung—esophageal cancer	0.000327	0.0035	CbGeAlD
Dasatinib—EPHA2—lung—esophageal cancer	0.000323	0.00346	CbGeAlD
Dasatinib—FYN—lung—esophageal cancer	0.000322	0.00346	CbGeAlD
Dasatinib—KIT—trachea—esophageal cancer	0.000318	0.0034	CbGeAlD
Dasatinib—MAP4K5—lung—esophageal cancer	0.000315	0.00338	CbGeAlD
Dasatinib—MAP3K3—lung—esophageal cancer	0.000315	0.00338	CbGeAlD
Dasatinib—TESK1—lymph node—esophageal cancer	0.000313	0.00336	CbGeAlD
Dasatinib—PDGFRB—trachea—esophageal cancer	0.00031	0.00332	CbGeAlD
Dasatinib—EPHB3—lymph node—esophageal cancer	0.000308	0.00331	CbGeAlD
Dasatinib—STK36—lymph node—esophageal cancer	0.000308	0.00331	CbGeAlD
Dasatinib—ABL1—bronchus—esophageal cancer	0.000308	0.0033	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—esophageal cancer	0.000301	0.00323	CbGeAlD
Dasatinib—EPHB6—lung—esophageal cancer	0.000301	0.00323	CbGeAlD
Dasatinib—CSF1R—digestive system—esophageal cancer	0.000301	0.00323	CbGeAlD
Dasatinib—LIMK2—lymph node—esophageal cancer	0.000298	0.0032	CbGeAlD
Dasatinib—YES1—lung—esophageal cancer	0.000291	0.00312	CbGeAlD
Dasatinib—STK35—lymph node—esophageal cancer	0.000289	0.0031	CbGeAlD
Dasatinib—CSK—lymph node—esophageal cancer	0.000287	0.00308	CbGeAlD
Dasatinib—PDGFRA—lung—esophageal cancer	0.000285	0.00306	CbGeAlD
Dasatinib—HCK—lymph node—esophageal cancer	0.000283	0.00304	CbGeAlD
Dasatinib—ABL2—lymph node—esophageal cancer	0.000282	0.00302	CbGeAlD
Dasatinib—SRC—lung—esophageal cancer	0.00028	0.003	CbGeAlD
Dasatinib—ABL1—trachea—esophageal cancer	0.000276	0.00296	CbGeAlD
Dasatinib—KIT—digestive system—esophageal cancer	0.000273	0.00293	CbGeAlD
Dasatinib—PDGFRB—digestive system—esophageal cancer	0.000267	0.00286	CbGeAlD
Dasatinib—RIPK2—lymph node—esophageal cancer	0.000266	0.00286	CbGeAlD
Dasatinib—SIK1—lymph node—esophageal cancer	0.00026	0.00279	CbGeAlD
Dasatinib—EPHA4—lymph node—esophageal cancer	0.000258	0.00276	CbGeAlD
Dasatinib—MAP2K5—lung—esophageal cancer	0.000257	0.00276	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—esophageal cancer	0.000255	0.00273	CbGeAlD
Dasatinib—ERBB3—lymph node—esophageal cancer	0.000255	0.00273	CbGeAlD
Dasatinib—MAP3K2—lymph node—esophageal cancer	0.000253	0.00271	CbGeAlD
Dasatinib—CSF1R—lung—esophageal cancer	0.000251	0.00269	CbGeAlD
Dasatinib—ABL1—digestive system—esophageal cancer	0.000238	0.00255	CbGeAlD
Dasatinib—MAPK14—lymph node—esophageal cancer	0.000238	0.00255	CbGeAlD
Dasatinib—FGR—lymph node—esophageal cancer	0.000237	0.00254	CbGeAlD
Dasatinib—LCK—lymph node—esophageal cancer	0.000237	0.00254	CbGeAlD
Dasatinib—FMO3—lymph node—esophageal cancer	0.000228	0.00245	CbGeAlD
Dasatinib—KIT—lung—esophageal cancer	0.000228	0.00245	CbGeAlD
Dasatinib—EPHB4—lymph node—esophageal cancer	0.000225	0.00241	CbGeAlD
Dasatinib—JAK2—lymph node—esophageal cancer	0.000224	0.0024	CbGeAlD
Dasatinib—PDGFRB—lung—esophageal cancer	0.000223	0.00239	CbGeAlD
Dasatinib—Stomatitis—Cisplatin—esophageal cancer	0.000221	0.00248	CcSEcCtD
Dasatinib—EPHA2—lymph node—esophageal cancer	0.000221	0.00237	CbGeAlD
Dasatinib—Conjunctivitis—Cisplatin—esophageal cancer	0.000221	0.00247	CcSEcCtD
Dasatinib—FYN—lymph node—esophageal cancer	0.000221	0.00236	CbGeAlD
Dasatinib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000217	0.00243	CcSEcCtD
Dasatinib—MAP4K5—lymph node—esophageal cancer	0.000215	0.00231	CbGeAlD
Dasatinib—MAP3K3—lymph node—esophageal cancer	0.000215	0.00231	CbGeAlD
Dasatinib—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000215	0.00241	CcSEcCtD
Dasatinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000215	0.00241	CcSEcCtD
Dasatinib—Skin exfoliation—Methotrexate—esophageal cancer	0.000212	0.00238	CcSEcCtD
Dasatinib—Face oedema—Capecitabine—esophageal cancer	0.000209	0.00235	CcSEcCtD
Dasatinib—EPHB6—lymph node—esophageal cancer	0.000206	0.00221	CbGeAlD
Dasatinib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000203	0.00228	CcSEcCtD
Dasatinib—CYP1B1—digestive system—esophageal cancer	0.000201	0.00216	CbGeAlD
Dasatinib—Neoplasm—Methotrexate—esophageal cancer	0.000201	0.00226	CcSEcCtD
Dasatinib—Ecchymosis—Methotrexate—esophageal cancer	0.000201	0.00226	CcSEcCtD
Dasatinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000201	0.00226	CcSEcCtD
Dasatinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.0002	0.00224	CcSEcCtD
Dasatinib—Urethral disorder—Cisplatin—esophageal cancer	0.0002	0.00224	CcSEcCtD
Dasatinib—Gynaecomastia—Methotrexate—esophageal cancer	0.000199	0.00223	CcSEcCtD
Dasatinib—YES1—lymph node—esophageal cancer	0.000199	0.00213	CbGeAlD
Dasatinib—Dry skin—Capecitabine—esophageal cancer	0.000199	0.00223	CcSEcCtD
Dasatinib—ABL1—lung—esophageal cancer	0.000199	0.00213	CbGeAlD
Dasatinib—Pulmonary oedema—Methotrexate—esophageal cancer	0.000198	0.00222	CcSEcCtD
Dasatinib—Hypokalaemia—Capecitabine—esophageal cancer	0.000197	0.00222	CcSEcCtD
Dasatinib—Visual impairment—Cisplatin—esophageal cancer	0.000196	0.0022	CcSEcCtD
Dasatinib—Breast disorder—Capecitabine—esophageal cancer	0.000196	0.0022	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000195	0.00219	CcSEcCtD
Dasatinib—PDGFRA—lymph node—esophageal cancer	0.000195	0.00209	CbGeAlD
Dasatinib—Sepsis—Methotrexate—esophageal cancer	0.000193	0.00217	CcSEcCtD
Dasatinib—Gastritis—Capecitabine—esophageal cancer	0.000192	0.00215	CcSEcCtD
Dasatinib—SRC—lymph node—esophageal cancer	0.000191	0.00205	CbGeAlD
Dasatinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000191	0.00215	CcSEcCtD
Dasatinib—Muscular weakness—Capecitabine—esophageal cancer	0.000191	0.00215	CcSEcCtD
Dasatinib—Eye disorder—Cisplatin—esophageal cancer	0.00019	0.00213	CcSEcCtD
Dasatinib—Tinnitus—Cisplatin—esophageal cancer	0.00019	0.00213	CcSEcCtD
Dasatinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000189	0.00212	CcSEcCtD
Dasatinib—Flushing—Cisplatin—esophageal cancer	0.000189	0.00212	CcSEcCtD
Dasatinib—Abdominal distension—Capecitabine—esophageal cancer	0.000189	0.00212	CcSEcCtD
Dasatinib—Dysphagia—Capecitabine—esophageal cancer	0.000188	0.0021	CcSEcCtD
Dasatinib—Asthma—Capecitabine—esophageal cancer	0.000188	0.0021	CcSEcCtD
Dasatinib—CYP1A1—epithelium—esophageal cancer	0.000187	0.00201	CbGeAlD
Dasatinib—Thrombophlebitis—Methotrexate—esophageal cancer	0.000187	0.00209	CcSEcCtD
Dasatinib—Bronchospasm—Capecitabine—esophageal cancer	0.000184	0.00207	CcSEcCtD
Dasatinib—CYP1A1—bronchus—esophageal cancer	0.000184	0.00198	CbGeAlD
Dasatinib—Photosensitivity—Methotrexate—esophageal cancer	0.000184	0.00206	CcSEcCtD
Dasatinib—Immune system disorder—Cisplatin—esophageal cancer	0.000184	0.00206	CcSEcCtD
Dasatinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000184	0.00206	CcSEcCtD
Dasatinib—Angina pectoris—Capecitabine—esophageal cancer	0.000183	0.00205	CcSEcCtD
Dasatinib—Arrhythmia—Cisplatin—esophageal cancer	0.000182	0.00204	CcSEcCtD
Dasatinib—Alopecia—Cisplatin—esophageal cancer	0.00018	0.00202	CcSEcCtD
Dasatinib—Pancytopenia—Capecitabine—esophageal cancer	0.000178	0.002	CcSEcCtD
Dasatinib—Malnutrition—Cisplatin—esophageal cancer	0.000177	0.00199	CcSEcCtD
Dasatinib—Erythema—Cisplatin—esophageal cancer	0.000177	0.00199	CcSEcCtD
Dasatinib—MAP2K5—lymph node—esophageal cancer	0.000176	0.00189	CbGeAlD
Dasatinib—Neutropenia—Capecitabine—esophageal cancer	0.000175	0.00197	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000174	0.00196	CcSEcCtD
Dasatinib—CSF1R—lymph node—esophageal cancer	0.000172	0.00184	CbGeAlD
Dasatinib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000171	0.00192	CcSEcCtD
Dasatinib—Weight increased—Capecitabine—esophageal cancer	0.000171	0.00191	CcSEcCtD
Dasatinib—Visual disturbance—Methotrexate—esophageal cancer	0.00017	0.00191	CcSEcCtD
Dasatinib—Muscle spasms—Cisplatin—esophageal cancer	0.00017	0.00191	CcSEcCtD
Dasatinib—Weight decreased—Capecitabine—esophageal cancer	0.00017	0.0019	CcSEcCtD
Dasatinib—CYP1B1—lung—esophageal cancer	0.000168	0.0018	CbGeAlD
Dasatinib—Pneumonia—Capecitabine—esophageal cancer	0.000168	0.00189	CcSEcCtD
Dasatinib—Infestation—Capecitabine—esophageal cancer	0.000167	0.00188	CcSEcCtD
Dasatinib—Infestation NOS—Capecitabine—esophageal cancer	0.000167	0.00188	CcSEcCtD
Dasatinib—Vision blurred—Cisplatin—esophageal cancer	0.000167	0.00187	CcSEcCtD
Dasatinib—Tremor—Cisplatin—esophageal cancer	0.000166	0.00186	CcSEcCtD
Dasatinib—CYP1A1—trachea—esophageal cancer	0.000166	0.00177	CbGeAlD
Dasatinib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000165	0.00185	CcSEcCtD
Dasatinib—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000165	0.00185	CcSEcCtD
Dasatinib—Ill-defined disorder—Cisplatin—esophageal cancer	0.000164	0.00184	CcSEcCtD
Dasatinib—Renal failure—Capecitabine—esophageal cancer	0.000164	0.00184	CcSEcCtD
Dasatinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000164	0.00184	CcSEcCtD
Dasatinib—Myocardial infarction—Capecitabine—esophageal cancer	0.000164	0.00184	CcSEcCtD
Dasatinib—Anaemia—Cisplatin—esophageal cancer	0.000164	0.00184	CcSEcCtD
Dasatinib—Stomatitis—Capecitabine—esophageal cancer	0.000163	0.00183	CcSEcCtD
Dasatinib—Conjunctivitis—Capecitabine—esophageal cancer	0.000163	0.00182	CcSEcCtD
Dasatinib—Malaise—Cisplatin—esophageal cancer	0.00016	0.00179	CcSEcCtD
Dasatinib—Haematuria—Capecitabine—esophageal cancer	0.000159	0.00179	CcSEcCtD
Dasatinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000158	0.00177	CcSEcCtD
Dasatinib—Epistaxis—Capecitabine—esophageal cancer	0.000158	0.00177	CcSEcCtD
Dasatinib—KIT—lymph node—esophageal cancer	0.000156	0.00167	CbGeAlD
Dasatinib—Convulsion—Cisplatin—esophageal cancer	0.000154	0.00172	CcSEcCtD
Dasatinib—PDGFRB—lymph node—esophageal cancer	0.000152	0.00163	CbGeAlD
Dasatinib—Myalgia—Cisplatin—esophageal cancer	0.000151	0.00169	CcSEcCtD
Dasatinib—Haemoglobin—Capecitabine—esophageal cancer	0.000151	0.00169	CcSEcCtD
Dasatinib—Anxiety—Cisplatin—esophageal cancer	0.00015	0.00169	CcSEcCtD
Dasatinib—Haemorrhage—Capecitabine—esophageal cancer	0.00015	0.00168	CcSEcCtD
Dasatinib—Hepatitis—Capecitabine—esophageal cancer	0.00015	0.00168	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00015	0.00168	CcSEcCtD
Dasatinib—Discomfort—Cisplatin—esophageal cancer	0.000149	0.00167	CcSEcCtD
Dasatinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000148	0.00166	CcSEcCtD
Dasatinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000148	0.00166	CcSEcCtD
Dasatinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000148	0.00165	CcSEcCtD
Dasatinib—Urethral disorder—Capecitabine—esophageal cancer	0.000147	0.00165	CcSEcCtD
Dasatinib—Breast disorder—Methotrexate—esophageal cancer	0.000146	0.00164	CcSEcCtD
Dasatinib—Oedema—Cisplatin—esophageal cancer	0.000145	0.00162	CcSEcCtD
Dasatinib—Visual impairment—Capecitabine—esophageal cancer	0.000145	0.00162	CcSEcCtD
Dasatinib—CYP1A2—digestive system—esophageal cancer	0.000144	0.00155	CbGeAlD
Dasatinib—Infection—Cisplatin—esophageal cancer	0.000144	0.00161	CcSEcCtD
Dasatinib—CYP1A1—digestive system—esophageal cancer	0.000142	0.00153	CbGeAlD
Dasatinib—Erythema multiforme—Capecitabine—esophageal cancer	0.000142	0.00159	CcSEcCtD
Dasatinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000142	0.00159	CcSEcCtD
Dasatinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000142	0.00159	CcSEcCtD
Dasatinib—Tachycardia—Cisplatin—esophageal cancer	0.000141	0.00158	CcSEcCtD
Dasatinib—Skin disorder—Cisplatin—esophageal cancer	0.000141	0.00158	CcSEcCtD
Dasatinib—Eye disorder—Capecitabine—esophageal cancer	0.00014	0.00157	CcSEcCtD
Dasatinib—Tinnitus—Capecitabine—esophageal cancer	0.00014	0.00157	CcSEcCtD
Dasatinib—Hyperhidrosis—Cisplatin—esophageal cancer	0.00014	0.00157	CcSEcCtD
Dasatinib—Asthma—Methotrexate—esophageal cancer	0.00014	0.00157	CcSEcCtD
Dasatinib—Flushing—Capecitabine—esophageal cancer	0.000139	0.00156	CcSEcCtD
Dasatinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000139	0.00156	CcSEcCtD
Dasatinib—CYP3A5—digestive system—esophageal cancer	0.000139	0.00149	CbGeAlD
Dasatinib—Anorexia—Cisplatin—esophageal cancer	0.000138	0.00155	CcSEcCtD
Dasatinib—Pancreatitis—Methotrexate—esophageal cancer	0.000137	0.00154	CcSEcCtD
Dasatinib—Angiopathy—Capecitabine—esophageal cancer	0.000136	0.00153	CcSEcCtD
Dasatinib—ABL1—lymph node—esophageal cancer	0.000136	0.00146	CbGeAlD
Dasatinib—Immune system disorder—Capecitabine—esophageal cancer	0.000136	0.00152	CcSEcCtD
Dasatinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000135	0.00152	CcSEcCtD
Dasatinib—Hypotension—Cisplatin—esophageal cancer	0.000135	0.00152	CcSEcCtD
Dasatinib—Chills—Capecitabine—esophageal cancer	0.000135	0.00151	CcSEcCtD
Dasatinib—Arrhythmia—Capecitabine—esophageal cancer	0.000134	0.0015	CcSEcCtD
Dasatinib—Alopecia—Capecitabine—esophageal cancer	0.000133	0.00149	CcSEcCtD
Dasatinib—Pancytopenia—Methotrexate—esophageal cancer	0.000133	0.00149	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000132	0.00148	CcSEcCtD
Dasatinib—Mental disorder—Capecitabine—esophageal cancer	0.000132	0.00148	CcSEcCtD
Dasatinib—Erythema—Capecitabine—esophageal cancer	0.000131	0.00147	CcSEcCtD
Dasatinib—Malnutrition—Capecitabine—esophageal cancer	0.000131	0.00147	CcSEcCtD
Dasatinib—Neutropenia—Methotrexate—esophageal cancer	0.000131	0.00146	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00013	0.00146	CcSEcCtD
Dasatinib—Dyspnoea—Cisplatin—esophageal cancer	0.000129	0.00145	CcSEcCtD
Dasatinib—Dysgeusia—Capecitabine—esophageal cancer	0.000128	0.00144	CcSEcCtD
Dasatinib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000127	0.00143	CcSEcCtD
Dasatinib—Decreased appetite—Cisplatin—esophageal cancer	0.000126	0.00141	CcSEcCtD
Dasatinib—Muscle spasms—Capecitabine—esophageal cancer	0.000126	0.00141	CcSEcCtD
Dasatinib—ABCG2—lung—esophageal cancer	0.000125	0.00134	CbGeAlD
Dasatinib—Pneumonia—Methotrexate—esophageal cancer	0.000125	0.0014	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000125	0.0014	CcSEcCtD
Dasatinib—Infestation—Methotrexate—esophageal cancer	0.000124	0.0014	CcSEcCtD
Dasatinib—Infestation NOS—Methotrexate—esophageal cancer	0.000124	0.0014	CcSEcCtD
Dasatinib—Pain—Cisplatin—esophageal cancer	0.000124	0.00139	CcSEcCtD
Dasatinib—Vision blurred—Capecitabine—esophageal cancer	0.000123	0.00138	CcSEcCtD
Dasatinib—Tremor—Capecitabine—esophageal cancer	0.000122	0.00137	CcSEcCtD
Dasatinib—Renal failure—Methotrexate—esophageal cancer	0.000122	0.00137	CcSEcCtD
Dasatinib—Stomatitis—Methotrexate—esophageal cancer	0.000121	0.00136	CcSEcCtD
Dasatinib—Ill-defined disorder—Capecitabine—esophageal cancer	0.000121	0.00136	CcSEcCtD
Dasatinib—Conjunctivitis—Methotrexate—esophageal cancer	0.000121	0.00136	CcSEcCtD
Dasatinib—Anaemia—Capecitabine—esophageal cancer	0.000121	0.00135	CcSEcCtD
Dasatinib—CYP1A2—lung—esophageal cancer	0.000121	0.00129	CbGeAlD
Dasatinib—Feeling abnormal—Cisplatin—esophageal cancer	0.000119	0.00134	CcSEcCtD
Dasatinib—CYP1A1—lung—esophageal cancer	0.000119	0.00127	CbGeAlD
Dasatinib—Haematuria—Methotrexate—esophageal cancer	0.000119	0.00133	CcSEcCtD
Dasatinib—Malaise—Capecitabine—esophageal cancer	0.000118	0.00132	CcSEcCtD
Dasatinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000118	0.00132	CcSEcCtD
Dasatinib—Epistaxis—Methotrexate—esophageal cancer	0.000117	0.00132	CcSEcCtD
Dasatinib—Vertigo—Capecitabine—esophageal cancer	0.000117	0.00132	CcSEcCtD
Dasatinib—Syncope—Capecitabine—esophageal cancer	0.000117	0.00131	CcSEcCtD
Dasatinib—CYP3A5—lung—esophageal cancer	0.000116	0.00125	CbGeAlD
Dasatinib—Palpitations—Capecitabine—esophageal cancer	0.000115	0.0013	CcSEcCtD
Dasatinib—CYP1B1—lymph node—esophageal cancer	0.000115	0.00123	CbGeAlD
Dasatinib—Loss of consciousness—Capecitabine—esophageal cancer	0.000115	0.00129	CcSEcCtD
Dasatinib—Body temperature increased—Cisplatin—esophageal cancer	0.000114	0.00128	CcSEcCtD
Dasatinib—Cough—Capecitabine—esophageal cancer	0.000114	0.00128	CcSEcCtD
Dasatinib—Hypertension—Capecitabine—esophageal cancer	0.000113	0.00127	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—esophageal cancer	0.000112	0.00126	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—esophageal cancer	0.000112	0.00125	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—esophageal cancer	0.000112	0.00125	CcSEcCtD
Dasatinib—Arthralgia—Capecitabine—esophageal cancer	0.000111	0.00125	CcSEcCtD
Dasatinib—Myalgia—Capecitabine—esophageal cancer	0.000111	0.00125	CcSEcCtD
Dasatinib—Chest pain—Capecitabine—esophageal cancer	0.000111	0.00125	CcSEcCtD
Dasatinib—Anxiety—Capecitabine—esophageal cancer	0.000111	0.00124	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00011	0.00124	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—esophageal cancer	0.00011	0.00124	CcSEcCtD
Dasatinib—Discomfort—Capecitabine—esophageal cancer	0.00011	0.00123	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—esophageal cancer	0.00011	0.00123	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—esophageal cancer	0.000108	0.00121	CcSEcCtD
Dasatinib—Confusional state—Capecitabine—esophageal cancer	0.000108	0.00121	CcSEcCtD
Dasatinib—Oedema—Capecitabine—esophageal cancer	0.000107	0.0012	CcSEcCtD
Dasatinib—Hypersensitivity—Cisplatin—esophageal cancer	0.000107	0.0012	CcSEcCtD
Dasatinib—Infection—Capecitabine—esophageal cancer	0.000106	0.00119	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—esophageal cancer	0.000106	0.00119	CcSEcCtD
Dasatinib—Shock—Capecitabine—esophageal cancer	0.000105	0.00118	CcSEcCtD
Dasatinib—Nervous system disorder—Capecitabine—esophageal cancer	0.000105	0.00117	CcSEcCtD
Dasatinib—CYP3A4—digestive system—esophageal cancer	0.000104	0.00112	CbGeAlD
Dasatinib—Eye disorder—Methotrexate—esophageal cancer	0.000104	0.00117	CcSEcCtD
Dasatinib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000104	0.00117	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—esophageal cancer	0.000104	0.00117	CcSEcCtD
Dasatinib—Tachycardia—Capecitabine—esophageal cancer	0.000104	0.00117	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—esophageal cancer	0.000104	0.00116	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—esophageal cancer	0.000104	0.00116	CcSEcCtD
Dasatinib—Skin disorder—Capecitabine—esophageal cancer	0.000104	0.00116	CcSEcCtD
Dasatinib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000103	0.00116	CcSEcCtD
Dasatinib—Anorexia—Capecitabine—esophageal cancer	0.000102	0.00114	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—esophageal cancer	0.000101	0.00114	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—esophageal cancer	0.000101	0.00113	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000101	0.00113	CcSEcCtD
Dasatinib—Chills—Methotrexate—esophageal cancer	0.0001	0.00112	CcSEcCtD
Dasatinib—Hypotension—Capecitabine—esophageal cancer	9.97e-05	0.00112	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—esophageal cancer	9.9e-05	0.00111	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—esophageal cancer	9.88e-05	0.00111	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—esophageal cancer	9.79e-05	0.0011	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—esophageal cancer	9.73e-05	0.00109	CcSEcCtD
Dasatinib—Erythema—Methotrexate—esophageal cancer	9.73e-05	0.00109	CcSEcCtD
Dasatinib—ABCB1—epithelium—esophageal cancer	9.72e-05	0.00104	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	9.72e-05	0.00109	CcSEcCtD
Dasatinib—Insomnia—Capecitabine—esophageal cancer	9.65e-05	0.00108	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—esophageal cancer	9.53e-05	0.00107	CcSEcCtD
Dasatinib—Dyspnoea—Capecitabine—esophageal cancer	9.51e-05	0.00107	CcSEcCtD
Dasatinib—Dyspepsia—Capecitabine—esophageal cancer	9.39e-05	0.00105	CcSEcCtD
Dasatinib—Decreased appetite—Capecitabine—esophageal cancer	9.27e-05	0.00104	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	9.21e-05	0.00103	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—esophageal cancer	9.2e-05	0.00103	CcSEcCtD
Dasatinib—Fatigue—Capecitabine—esophageal cancer	9.2e-05	0.00103	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—esophageal cancer	9.17e-05	0.00103	CcSEcCtD
Dasatinib—Rash—Cisplatin—esophageal cancer	9.12e-05	0.00102	CcSEcCtD
Dasatinib—Constipation—Capecitabine—esophageal cancer	9.12e-05	0.00102	CcSEcCtD
Dasatinib—Pain—Capecitabine—esophageal cancer	9.12e-05	0.00102	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—esophageal cancer	9.11e-05	0.00102	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—esophageal cancer	9.03e-05	0.00101	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—esophageal cancer	8.99e-05	0.00101	CcSEcCtD
Dasatinib—Feeling abnormal—Capecitabine—esophageal cancer	8.79e-05	0.000986	CcSEcCtD
Dasatinib—Malaise—Methotrexate—esophageal cancer	8.77e-05	0.000984	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—esophageal cancer	8.74e-05	0.00098	CcSEcCtD
Dasatinib—Gastrointestinal pain—Capecitabine—esophageal cancer	8.72e-05	0.000978	CcSEcCtD
Dasatinib—ABCB1—trachea—esophageal cancer	8.6e-05	0.000921	CbGeAlD
Dasatinib—Nausea—Cisplatin—esophageal cancer	8.59e-05	0.000964	CcSEcCtD
Dasatinib—ABCG2—lymph node—esophageal cancer	8.57e-05	0.000918	CbGeAlD
Dasatinib—Cough—Methotrexate—esophageal cancer	8.49e-05	0.000952	CcSEcCtD
Dasatinib—Urticaria—Capecitabine—esophageal cancer	8.47e-05	0.00095	CcSEcCtD
Dasatinib—Abdominal pain—Capecitabine—esophageal cancer	8.43e-05	0.000946	CcSEcCtD
Dasatinib—Body temperature increased—Capecitabine—esophageal cancer	8.43e-05	0.000946	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—esophageal cancer	8.43e-05	0.000945	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—esophageal cancer	8.28e-05	0.000929	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—esophageal cancer	8.28e-05	0.000929	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—esophageal cancer	8.28e-05	0.000929	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	8.23e-05	0.000923	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—esophageal cancer	8.18e-05	0.000918	CcSEcCtD
Dasatinib—CYP1A1—lymph node—esophageal cancer	8.13e-05	0.000872	CbGeAlD
Dasatinib—Confusional state—Methotrexate—esophageal cancer	8.01e-05	0.000898	CcSEcCtD
Dasatinib—Infection—Methotrexate—esophageal cancer	7.89e-05	0.000885	CcSEcCtD
Dasatinib—Hypersensitivity—Capecitabine—esophageal cancer	7.86e-05	0.000881	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—esophageal cancer	7.79e-05	0.000873	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—esophageal cancer	7.77e-05	0.000872	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—esophageal cancer	7.71e-05	0.000865	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—esophageal cancer	7.68e-05	0.000861	CcSEcCtD
Dasatinib—Asthenia—Capecitabine—esophageal cancer	7.65e-05	0.000858	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—esophageal cancer	7.57e-05	0.000849	CcSEcCtD
Dasatinib—Pruritus—Capecitabine—esophageal cancer	7.55e-05	0.000846	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—esophageal cancer	7.42e-05	0.000832	CcSEcCtD
Dasatinib—ABCB1—digestive system—esophageal cancer	7.4e-05	0.000793	CbGeAlD
Dasatinib—Diarrhoea—Capecitabine—esophageal cancer	7.3e-05	0.000818	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	7.23e-05	0.000811	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—esophageal cancer	7.18e-05	0.000805	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—esophageal cancer	7.08e-05	0.000794	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—esophageal cancer	7.06e-05	0.000792	CcSEcCtD
Dasatinib—Dizziness—Capecitabine—esophageal cancer	7.05e-05	0.000791	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—esophageal cancer	6.99e-05	0.000784	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—esophageal cancer	6.9e-05	0.000774	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.85e-05	0.000769	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—esophageal cancer	6.85e-05	0.000768	CcSEcCtD
Dasatinib—Pain—Methotrexate—esophageal cancer	6.79e-05	0.000762	CcSEcCtD
Dasatinib—Vomiting—Capecitabine—esophageal cancer	6.78e-05	0.000761	CcSEcCtD
Dasatinib—Rash—Capecitabine—esophageal cancer	6.72e-05	0.000754	CcSEcCtD
Dasatinib—Dermatitis—Capecitabine—esophageal cancer	6.72e-05	0.000754	CcSEcCtD
Dasatinib—Headache—Capecitabine—esophageal cancer	6.68e-05	0.000749	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—esophageal cancer	6.54e-05	0.000734	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—esophageal cancer	6.49e-05	0.000728	CcSEcCtD
Dasatinib—Nausea—Capecitabine—esophageal cancer	6.34e-05	0.000711	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—esophageal cancer	6.31e-05	0.000707	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—esophageal cancer	6.28e-05	0.000704	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—esophageal cancer	6.28e-05	0.000704	CcSEcCtD
Dasatinib—ABCB1—lung—esophageal cancer	6.18e-05	0.000662	CbGeAlD
Dasatinib—Hypersensitivity—Methotrexate—esophageal cancer	5.85e-05	0.000656	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—esophageal cancer	5.7e-05	0.000639	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—esophageal cancer	5.62e-05	0.00063	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—esophageal cancer	5.43e-05	0.000609	CcSEcCtD
Dasatinib—Dizziness—Methotrexate—esophageal cancer	5.25e-05	0.000589	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—esophageal cancer	5.05e-05	0.000566	CcSEcCtD
Dasatinib—Rash—Methotrexate—esophageal cancer	5.01e-05	0.000561	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—esophageal cancer	5e-05	0.000561	CcSEcCtD
Dasatinib—Headache—Methotrexate—esophageal cancer	4.97e-05	0.000558	CcSEcCtD
Dasatinib—Nausea—Methotrexate—esophageal cancer	4.72e-05	0.000529	CcSEcCtD
Dasatinib—ABCB1—lymph node—esophageal cancer	4.22e-05	0.000453	CbGeAlD
Dasatinib—FYN—Disease—CDKN1A—esophageal cancer	1.51e-06	8.59e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—esophageal cancer	1.51e-06	8.59e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	1.51e-06	8.57e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB2—esophageal cancer	1.51e-06	8.57e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.51e-06	8.56e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.51e-06	8.55e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CREBBP—esophageal cancer	1.5e-06	8.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EP300—esophageal cancer	1.5e-06	8.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EP300—esophageal cancer	1.49e-06	8.48e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—esophageal cancer	1.49e-06	8.48e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—esophageal cancer	1.49e-06	8.48e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EP300—esophageal cancer	1.48e-06	8.42e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CREBBP—esophageal cancer	1.48e-06	8.41e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.48e-06	8.4e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.48e-06	8.39e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB2—esophageal cancer	1.47e-06	8.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.47e-06	8.33e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—PIK3CA—esophageal cancer	1.46e-06	8.29e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—BCL2—esophageal cancer	1.46e-06	8.26e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ABCB1—esophageal cancer	1.45e-06	8.21e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—esophageal cancer	1.45e-06	8.21e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CDKN1A—esophageal cancer	1.44e-06	8.2e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KDR—esophageal cancer	1.44e-06	8.2e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—esophageal cancer	1.44e-06	8.19e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—EP300—esophageal cancer	1.44e-06	8.18e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—CDKN1A—esophageal cancer	1.44e-06	8.17e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—CREBBP—esophageal cancer	1.43e-06	8.11e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	1.43e-06	8.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CREBBP—esophageal cancer	1.43e-06	8.1e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	1.42e-06	8.03e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB2—esophageal cancer	1.41e-06	8.03e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—esophageal cancer	1.41e-06	8.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CREBBP—esophageal cancer	1.41e-06	7.99e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.41e-06	7.98e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—NOS3—esophageal cancer	1.41e-06	7.98e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—PIK3CA—esophageal cancer	1.4e-06	7.97e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.4e-06	7.97e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—PIK3CA—esophageal cancer	1.4e-06	7.96e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TPI1—esophageal cancer	1.4e-06	7.95e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.4e-06	7.95e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS3—esophageal cancer	1.4e-06	7.92e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.39e-06	7.89e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.38e-06	7.86e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	1.38e-06	7.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—esophageal cancer	1.38e-06	7.85e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—esophageal cancer	1.38e-06	7.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	1.38e-06	7.81e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EP300—esophageal cancer	1.37e-06	7.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EP300—esophageal cancer	1.37e-06	7.77e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—CDKN1A—esophageal cancer	1.37e-06	7.75e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—esophageal cancer	1.36e-06	7.74e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	1.36e-06	7.72e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—esophageal cancer	1.35e-06	7.67e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NOS3—esophageal cancer	1.35e-06	7.65e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—esophageal cancer	1.34e-06	7.63e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.34e-06	7.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HIF1A—esophageal cancer	1.34e-06	7.59e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—esophageal cancer	1.33e-06	7.57e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—esophageal cancer	1.33e-06	7.57e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—esophageal cancer	1.33e-06	7.55e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—PIK3CA—esophageal cancer	1.33e-06	7.55e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NOS3—esophageal cancer	1.33e-06	7.53e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.32e-06	7.51e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.32e-06	7.49e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.32e-06	7.48e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO1—esophageal cancer	1.32e-06	7.48e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—PIK3CA—esophageal cancer	1.31e-06	7.46e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB2—esophageal cancer	1.31e-06	7.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—esophageal cancer	1.3e-06	7.39e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—esophageal cancer	1.3e-06	7.39e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EP300—esophageal cancer	1.3e-06	7.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PSME2—esophageal cancer	1.3e-06	7.37e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PSME1—esophageal cancer	1.3e-06	7.37e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—PIK3CA—esophageal cancer	1.3e-06	7.36e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.29e-06	7.33e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	1.29e-06	7.32e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	1.29e-06	7.31e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—esophageal cancer	1.29e-06	7.3e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—esophageal cancer	1.28e-06	7.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.28e-06	7.27e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—NOS3—esophageal cancer	1.28e-06	7.26e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KDR—esophageal cancer	1.28e-06	7.26e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NOS3—esophageal cancer	1.28e-06	7.25e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—esophageal cancer	1.28e-06	7.25e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—esophageal cancer	1.27e-06	7.23e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—esophageal cancer	1.27e-06	7.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—esophageal cancer	1.26e-06	7.18e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	1.26e-06	7.16e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NOS3—esophageal cancer	1.26e-06	7.16e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—CDKN1A—esophageal cancer	1.26e-06	7.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—esophageal cancer	1.26e-06	7.15e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—esophageal cancer	1.26e-06	7.13e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—esophageal cancer	1.24e-06	7.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	1.23e-06	7e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—esophageal cancer	1.23e-06	6.97e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EP300—esophageal cancer	1.23e-06	6.97e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PIK3CA—esophageal cancer	1.23e-06	6.97e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	1.22e-06	6.93e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.22e-06	6.91e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDKN1A—esophageal cancer	1.21e-06	6.86e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HMOX1—esophageal cancer	1.2e-06	6.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOTCH1—esophageal cancer	1.2e-06	6.84e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	1.2e-06	6.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—PIK3CA—esophageal cancer	1.2e-06	6.82e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EP300—esophageal cancer	1.2e-06	6.81e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—esophageal cancer	1.2e-06	6.8e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PIK3CA—esophageal cancer	1.2e-06	6.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—esophageal cancer	1.19e-06	6.78e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—esophageal cancer	1.19e-06	6.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—esophageal cancer	1.18e-06	6.69e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—esophageal cancer	1.17e-06	6.66e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—esophageal cancer	1.17e-06	6.65e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—esophageal cancer	1.17e-06	6.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—esophageal cancer	1.17e-06	6.63e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—esophageal cancer	1.17e-06	6.62e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	1.16e-06	6.6e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	1.16e-06	6.59e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—esophageal cancer	1.16e-06	6.57e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—esophageal cancer	1.15e-06	6.55e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—esophageal cancer	1.15e-06	6.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.14e-06	6.48e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	1.14e-06	6.45e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.13e-06	6.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.12e-06	6.36e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—esophageal cancer	1.12e-06	6.36e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1A—esophageal cancer	1.12e-06	6.33e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—esophageal cancer	1.11e-06	6.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—esophageal cancer	1.11e-06	6.31e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—esophageal cancer	1.11e-06	6.29e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—esophageal cancer	1.11e-06	6.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—esophageal cancer	1.1e-06	6.27e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	1.1e-06	6.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—esophageal cancer	1.1e-06	6.23e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—esophageal cancer	1.1e-06	6.22e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.09e-06	6.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CREBBP—esophageal cancer	1.09e-06	6.2e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.09e-06	6.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	1.08e-06	6.11e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.07e-06	6.09e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—esophageal cancer	1.07e-06	6.07e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—esophageal cancer	1.07e-06	6.07e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—esophageal cancer	1.07e-06	6.05e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—esophageal cancer	1.06e-06	6.03e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1A—esophageal cancer	1.06e-06	6.02e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—esophageal cancer	1.06e-06	5.99e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.05e-06	5.98e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	1.05e-06	5.94e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—esophageal cancer	1.05e-06	5.94e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—esophageal cancer	1.04e-06	5.93e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—esophageal cancer	1.04e-06	5.91e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	1.03e-06	5.86e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—esophageal cancer	1.02e-06	5.82e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.02e-06	5.81e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—esophageal cancer	1.02e-06	5.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1A—esophageal cancer	1.02e-06	5.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.02e-06	5.77e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.02e-06	5.77e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—esophageal cancer	1.02e-06	5.77e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—esophageal cancer	1.01e-06	5.75e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	1.01e-06	5.75e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—esophageal cancer	1.01e-06	5.73e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—esophageal cancer	1.01e-06	5.72e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSME2—esophageal cancer	1e-06	5.69e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PSME1—esophageal cancer	1e-06	5.69e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	9.9e-07	5.62e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—esophageal cancer	9.83e-07	5.58e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—esophageal cancer	9.8e-07	5.56e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—esophageal cancer	9.77e-07	5.55e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—esophageal cancer	9.73e-07	5.52e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—esophageal cancer	9.71e-07	5.51e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CREBBP—esophageal cancer	9.67e-07	5.49e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—esophageal cancer	9.61e-07	5.46e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—esophageal cancer	9.61e-07	5.46e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—esophageal cancer	9.59e-07	5.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.43e-07	5.35e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—esophageal cancer	9.25e-07	5.25e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—esophageal cancer	9.23e-07	5.24e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—esophageal cancer	9.16e-07	5.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—esophageal cancer	9.14e-07	5.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—esophageal cancer	9.12e-07	5.18e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	9.12e-07	5.18e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	9.08e-07	5.15e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—esophageal cancer	9.05e-07	5.14e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—esophageal cancer	8.93e-07	5.07e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	8.92e-07	5.06e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—esophageal cancer	8.87e-07	5.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	8.83e-07	5.01e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—esophageal cancer	8.79e-07	4.99e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—esophageal cancer	8.78e-07	4.99e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—esophageal cancer	8.73e-07	4.96e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—esophageal cancer	8.66e-07	4.92e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.65e-07	4.91e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—esophageal cancer	8.6e-07	4.88e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	8.59e-07	4.88e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—esophageal cancer	8.51e-07	4.83e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—esophageal cancer	8.46e-07	4.81e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—esophageal cancer	8.4e-07	4.77e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	8.38e-07	4.76e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—esophageal cancer	8.35e-07	4.74e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	8.31e-07	4.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—esophageal cancer	8.28e-07	4.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—esophageal cancer	8.17e-07	4.64e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	8.13e-07	4.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—esophageal cancer	8.08e-07	4.59e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—esophageal cancer	7.92e-07	4.5e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—esophageal cancer	7.91e-07	4.49e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—esophageal cancer	7.85e-07	4.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—esophageal cancer	7.81e-07	4.44e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	7.74e-07	4.4e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CREBBP—esophageal cancer	7.72e-07	4.39e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	7.58e-07	4.3e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	7.49e-07	4.25e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—esophageal cancer	7.46e-07	4.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—esophageal cancer	7.43e-07	4.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.42e-07	4.21e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—esophageal cancer	7.33e-07	4.16e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—esophageal cancer	7.32e-07	4.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—esophageal cancer	7.22e-07	4.1e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	7.2e-07	4.09e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—esophageal cancer	7.18e-07	4.08e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—esophageal cancer	7.16e-07	4.06e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	7.12e-07	4.04e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—esophageal cancer	7.09e-07	4.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.97e-07	3.96e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—esophageal cancer	6.97e-07	3.96e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—esophageal cancer	6.95e-07	3.95e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—esophageal cancer	6.91e-07	3.93e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—esophageal cancer	6.86e-07	3.9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—esophageal cancer	6.59e-07	3.74e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—esophageal cancer	6.48e-07	3.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—esophageal cancer	6.34e-07	3.6e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—esophageal cancer	6.32e-07	3.59e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	6.21e-07	3.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.17e-07	3.5e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—esophageal cancer	6.01e-07	3.41e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—esophageal cancer	5.52e-07	3.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—esophageal cancer	5.5e-07	3.12e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—esophageal cancer	5.32e-07	3.02e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—esophageal cancer	5.26e-07	2.99e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	5.16e-07	2.93e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.05e-07	2.87e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—esophageal cancer	4.87e-07	2.77e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.76e-07	2.7e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—esophageal cancer	4.26e-07	2.42e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—esophageal cancer	4.2e-07	2.38e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.9e-07	2.21e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.89e-07	2.21e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—esophageal cancer	3.24e-07	1.84e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.11e-07	1.76e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.4e-07	1.36e-06	CbGpPWpGaD
